TCIP

The TCRA Charitable Donation Plan TCRA, our startup LLC, holds multiple US and international patents. The initial impact for TCRA patents must come from the Big 4 clinical lab automation manufacturers: Siemens, Abbott, Beckman Coulter, and Roche ("The Big 4"). These clinical lab manufacturers have the collective power to catalyze a new global standard in lab technology.

TCRA has the potential to be worth **$300-350 billion** by Big 4 announcing an upgrade of TLA to patented DLA technology. We plan to use ~**7%** of that value to provide funding to save the lives of the **140,000** babies who die from Rh disease every year. This charitable work is already being done by WIRhE, an organization that will disseminate a drug developed by the founder of TCRA, Dr. John Gorman.

To achieve this valuation of **$300-350 billion**, TCRA merely needs the Big 4 to issue press releases announcing their intent to use DLA intellectual property in their next generation clinical analyzers; in their client clinal labs worldwide and collect **$1 trillion** royalties for TCRA shareholders over the next 20 years,

We have budgeted **7%** equity in TCRA per each Big 4 member, **7%** equity per one or more top bank underwriters and Private Equity firms and **10%** per early investors in TCRA. The remaining **50%** equity will be distributed to those large foundations, best able to do the most good, e.g. Gates, Rockefeller, The Asia Society.

The short period post announcements is crucial. **$10 billion** dollars cash will be raised selling TCRA shares for WIRhE. TCRA shareholder will sell a small percengtage of their shares to raise another **$10 billion**. The underwriters will have arranged for general partner lead investors to invest **$20 billion** first money in TCRA at **1/3** market value. This is part of the deal structure designed to make it win-win for all parties.

The TCRA charitable donation plan is feasible due to the incredible need for technological advancement in the slow-moving clinical lab industry. When TCRA's patented DLA technology becomes the standard in the **50,000** globally operating labs, TCRA shareholders will have access to up to **$1 trillion** in royalty cash flow based on tapping **$8.8 trillion** in the recurring total revenues clinical labs will earn over the next 20 years.

The Big 4 will be motivated to announce their adoption of DLA by **1**. owning shares in TCRA and **2.** receiving royalty-free licenses to design and manufacture DLA analyzers. Since the building of new laboratories is funded by hospitals, medicals centers, and companies such as Quest Diagnostics, the Big 4 have the potential to dramatically increase the value of their shares in TCRTAS simply announcing the DLA adoption.

Patent royalties will be passed, tax-free to TCRA, to shareholders over the next 20 years. Just like a CDO, TCRA will bundle royalties from approximately **50,000** clinical labs worldwide into a single cash flow obligation to TCRA shareholders. Enforcement of royalty collection is ensured at the point of sale of each new DLA system: the Big 4 commit not to sell lab automation equipment to any clinical lab that has not signed a contract to pay the royalties. This simple measure will make royalty enforcement easy.

As an asset light patent holding company, TCRA does not need significant working capital to operate. All of the financial heavy lifting (the cost of labor, property, and project management) is managed separately by the Big 4 in alignment with their own business interests. TCRA margins have the potential to be more than 99% EBT.

If we publicize the TCRA charitable donation plan it has the potential of motivating the Big 4 by allowing them to claim their role in funding WIRhE. A publication in a major news outlet such as The Wall Street Journal may be the best way to make Big 4 aware of not only the extraordinary business opportunity

The monetization of TCRA will result in the ultimate win-win. If we achieve our targets, there will be enough money to fund WIRhE – **140,000** Rh babies' lives will be saved annually in the developing world. Upwards of **$500 billion** in cash flow will go to charity and other public causes ensuring long-term philanthropic impact. Additional charitable giving may directed towards Inga 3, which will bring electricity to 600 million people in Africa. The Big 4 will be handsomely rewarded for both the economic and societal benefits brought about through their adoption of DLA. Clinical labs can look forward to much improved operations with DLA. With DLA, the FDA will be able to regulate labs in a much better way, resulting in more reliable lab test results in the future. DLA will be an ideal forum for essential LDT innovations. At TCI, we are excited and humbled by the tremendous amount of good that can be achieved through our innovation.